Chargement en cours...
Impact of empagliflozin on diabetic kidney disease
Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule‐glomerular feedback, thereby protect against diabetes‐induced caidio‐renal injuries.[Image: see text]
Enregistré dans:
| Publié dans: | J Diabetes Investig |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5583951/ https://ncbi.nlm.nih.gov/pubmed/28035769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12615 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|